Medical therapy for bilateral uveal effusion syndrome in nanophthalmos

Can J Ophthalmol. 2017 Dec;52(6):e199-e201. doi: 10.1016/j.jcjo.2017.04.017. Epub 2017 Jun 23.

Authors

Joong Hyun Park¹, Eun Kyoung Lee²

Affiliations

¹ Department of Ophthalmology, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea.
² Department of Ophthalmology, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea. Electronic address: [email protected].

PMID: 29217039
DOI: 10.1016/j.jcjo.2017.04.017

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acetazolamide / therapeutic use*
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antihypertensive Agents / therapeutic use
Benzophenones / therapeutic use
Bromobenzenes / therapeutic use
Carbonic Anhydrase Inhibitors / therapeutic use
Choroid / pathology
Choroid Diseases / drug therapy*
Ciliary Body / pathology*
Drug Therapy, Combination
Fluorescein Angiography
Fundus Oculi
Humans
Latanoprost / therapeutic use*
Male
Microphthalmos / diagnosis*
Middle Aged
Retina / pathology
Retinal Detachment / diagnosis
Retinal Detachment / drug therapy*
Syndrome
Tomography, Optical Coherence
Uveal Diseases / diagnosis
Uveal Diseases / drug therapy*

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antihypertensive Agents
Benzophenones
Bromobenzenes
Carbonic Anhydrase Inhibitors
Latanoprost
bromfenac
Acetazolamide